Latest California Healthline Stories
$38,398 for a Single Shot of a Very Old Cancer Drug
Lupron, a drug patented half a century ago, treats advanced prostate cancer. It’s sold to physicians for $260 in the U.K. and administered at no charge. Why are U.S. hospitals — which may pay nearly as little for the drug — charging so much more to administer it?
Reporter Follows Up on ‘Cancer Moonshot’ Progress and the Bias in Digital Health Records
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
Genetic Tests Create Treatment Opportunities and Confusion for Breast Cancer Patients
Doctors are divided on whether blanket testing of breast cancer patients is warranted, since scientists and physicians are sometimes unsure about how to interpret the results.
La última década ha sido testigo de una rápida expansión de las pruebas genéticas. Pero, ¿cuál es su real relevancia clínica?
New Abortion Laws Jeopardize Cancer Treatment for Pregnant Patients
As abortion restrictions take effect across the South in the wake of the Supreme Court’s decision to overturn Roe v. Wade, cancer doctors are trying to decipher the laws. They’re grappling with how to discuss options with pregnant patients, who may be forced to choose whether to proceed or forgo lifesaving cancer treatments that can prove toxic for the fetus.
Many Preventive Medical Services Cost Patients Nothing. Will a Texas Court Decision Change That?
A federal judge in Texas issued a decision this week that affects the Affordable Care Act. It says one way that preventive services are selected for no-cost coverage is unconstitutional.
Rural Americans Have Difficulty Accessing a Promising Cancer Treatment
Chimeric antigen receptor T-cell therapy has eliminated tumors in some late-stage cancer patients, but the cost and complexity of care mean rural Americans have trouble accessing the treatment.
The $18,000 Breast Biopsy: When Having Insurance Costs You a Bundle
An online calculator told a young woman that a procedure to rule out cancer would cost an uninsured person about $1,400. Instead, the hospital initially charged almost $18,000 and, with her high-deductible health insurance, she owed more than $5,000.
Para las familias médicamente vulnerables, la presión de la inflación es inevitable
Para millones de familias que viven con enfermedades crónicas, trastornos cardíacos, diabetes y cáncer, u otras condiciones debilitantes, la inflación está demostrando ser un doloroso flagelo que podría perjudicar su salud.
For Medically Vulnerable Families, Inflation’s Squeeze Is Inescapable
Inflation hasn’t hit Americans like this in decades. And families living with chronic diseases have little choice but to pay more for the medicine, supplies, and food they need to stay healthy.